Use of bone morphogenetic proteins in arthrodesis: clinical results.
Bone grafting is not routinely required in primary arthrodesis in the absence of infection, avascular necrosis, bone defect or previous non-union; when any of the above factors is present, autograft is the gold-standard method. However, donor site morbidity and the quantitative and qualitative limitations of autograft have led to the development of alternatives. This study documents the use of the bone morphogenetic protein BMP-7 in a total of 19 joint fusions (ankle, subtalar, talonavicular, pubic and sacroiliac). Healing rates of 90% and satisfactory subjective functional outcome in 70% of cases were recorded over a minimum follow-up of 15 months. These data should provide a sound foundation for future clinical trials evaluating the application of BMP-7 in the fusion of joints.
Kanakaris
Nikolaos K
NK
Department of Trauma and Orthopaedics, Leeds Teaching Hospitals NHS Trust, Great George Street, Leeds LS1 3EX, UK.
Mallina
Ravi
R
Calori
Giorgio M
GM
Kontakis
George
G
Giannoudis
Peter V
PV
D000328:Adult; D000368:Aged; D018771:Arthralgia / Q000601:surgery / Q000628:therapy; D001168:Arthritis / Q000209:etiology / Q000601:surgery*; D001174:Arthrodesis / Q000379:methods*; D055419:Bone Morphogenetic Protein 7 / Q000627:therapeutic use*; D016025:Bone Transplantation; D002908:Chronic Disease; D005260:Female; D033023:Foot Joints / Q000601:surgery; D006801:Humans; D008297:Male; D008875:Middle Aged; D056687:Off-Label Use; D017060:Patient Satisfaction; D011446:Prospective Studies; D011631:Pubic Symphysis / Q000601:surgery; D012446:Sacroiliac Joint / Q000601:surgery; D012907:Smoking / Q000009:adverse effects; D016896:Treatment Outcome
C525819:BMP7 protein, human; D055419:Bone Morphogenetic Protein 7